Australian moth uses the night sky as a guiding compass
An Australian moth uses the night sky as a guiding compass during its yearly migration, according to a new study.
When temperatures heat up, nocturnal Bogong moths fly about 620 miles (1,000km) to cool down in caves by the Australian Alps. They later return home to breed and die.
Birds routinely navigate by starlight, but the moths are the first known invertebrates, or creatures without a backbone, to find their way across such long distances using the stars.
Scientists have long wondered how the moths travel to a place they've never been.
A previous study hinted that Earth's magnetic field might help steer them in the right direction, along with some kind of visual landmark as a guide.
Since stars appear in predictable patterns each night, scientists suspected they might help lead the way.
They placed moths in a flight simulator that mimicked the night sky above them and blocked out the Earth's magnetic field, noting where they flew. Then they scrambled the stars and saw how the moths reacted.
When the stars were as they should be, the moths flapped in the right direction. But when the stars were in random places, the moths were disoriented. Their brain cells also got excited in response to specific orientations of the night sky.
The findings were published recently in the journal Nature.
The mountainous landscape near caves where Australian Bogong moths go to cool down and rest at the Ramshead Range of the Snowy Mountains in New South Wales.— ERIC WARRANT/AP
Sky as guide
It 'was a very clean, impressive demonstration that the moths really are using a view of the night sky to guide their movements,' said Kenneth Lohmann, who studies animal navigation at the University of North Carolina at Chapel Hill and was not involved with the new research.
Researchers don't know what features of the night sky the moths use to find their way. It could be a stripe of light from the Milky Way, a colourful nebula or something else entirely.
Whatever it is, the insects seem to rely on that along with Earth's magnetic field to make their journey.
Other animals harness the stars as a guide. Birds take celestial cues as they soar through the skies and dung beetles roll their remains short distances while using the Milky Way to stay on course.
It's an impressive feat for Bogong moths whose brains are smaller than size of a grain of rice to rely on the night sky for their odyssey, said study author David Dreyer with Lund University in Sweden.
'It's remarkable that an animal with such a tiny brain can actually do this,' Dreyer said. – AP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
17 hours ago
- The Star
'Tron: Ares' brings light cycles and Nine Inch Nails soundtrack, to Comic-Con
Atmosphere at the Tron: Ares panel in Hall H of the convention center during Comic Con International in San Diego, California on July 25, 2025. (Photo by Chris DELMAS/ AFP) The Grid took over Comic-Con on Friday, bringing the stars of the new Tron: Ares films to unveil footage and reveal the story behind the franchise's third movie. The film stars Jared Leto, Jeff Bridges, Greta Lee and Jodie Turner-Smith as the story brings the virtual environment of the Grid, complete with light cylces, into the real world. Disney showed off several minutes of footage, including a light cycle chase scene in the real world and another in the red-hued Grid. Propelling the onscreen action is a propulsive Nine Inch Nails soundtrack. "It's fun to see it on the big screen for the first time,' said director Joachim Rønning. Disney turned the Hall H panel into a spectacle, with red lasers filling the room and characters in suits with red lights entering the massive hall. Asked what excited her about joining the Tron franchise, Lee responded: "I just wanted to ride a light cycle.' Leto spoke affectionately about the original saying: "This movie just grabbed a hold of me and took me to a place that I'd never been before. It kind of rattled my imagination and it kind of showed me what was possible in the world.' He praised Bridges and Steven Lisberger, who created Tron and directed the 1982 original. Lisberger attended Friday's panel and laid out his case for why the franchise remains relevant. "My feeling about Tron is that the most important thing is we kick this technology around artistically before it kicks us around,' Lisberger said. "I am weary about hearing all the grim news about the future,' he said, and the way he thinks it can be avoided is to "inspire young people what can be done with this technology.' Friday's panel ended with the premiere of the music video for As Alive as You Need Me to Be , the first Nine Inch Nails song from the soundtrack. Tron has never been in the top tier of sci-fi franchises. The original 1982 film starring Bridges as Kevin Flynn, a man sucked into a computer vortex known as the Grid, was admired for its ground-breaking concept and effects, and was a modest hit with moderately good reviews. Perhaps more importantly, it won a cult following and has been maintained enough in cultural memory to remain a valuable property for Disney. The 2010 film Tron: Legacy , starring Bridges and Garrett Hedlund, made more than US$400mil globally. A TV show that followed, Tron: Uprising , lasted just one season. Rønning has helmed other Disney franchise films: 2017's Pirates of the Caribbean: Dead Men Tell No Tales and 2019's Maleficent: Mistress of Evil . The Norweigan director said he was interested because he dreamed about making a sci-fi film and enjoyed the twist of Ares bringing the Grid into the real world. Leto and Bridges are both Oscar winners, and Rønning is an Oscar nominee. – AP
The Star
4 days ago
- The Star
Meta unveils wristband for controlling computers with hand gestures
SAN FRANCISCO: The prototype looks like a giant rectangular wristwatch. But it doesn't tell the time: It lets you control a computer from across the room simply by moving your hand. With a gentle turn of the wrist, you can push a cursor across your laptop screen. If you tap your thumb against your forefinger, you can open an app on your desktop computer. And when you write your name in the air, as if you were holding a pencil, the letters will appear on your smartphone. Designed by researchers at Meta, the tech giant that owns Facebook, Instagram and WhatsApp, this experimental technology reads the electrical signals that pulse through your muscles when you move your fingers. These signals, generated by commands sent from your brain, can reveal what you are about to do even before you do it, as the company detailed in a research paper published Wednesday in the journal Nature . With a little practice, you can even move your laptop cursor simply by producing the right thought. 'You don't have to actually move,' Thomas Reardon, the Meta vice president of research who leads the project, said in an interview. 'You just have to intend the move.' Meta's wristband is part of a sweeping effort to develop technologies that let wearers control their personal devices without touching them. The aim is to provide simpler, quicker and less awkward ways of interacting with everything from laptops to smartphones – and maybe even to develop new digital devices that replace what we all use today. Most of these technologies are years away from widespread use. They typically involve tiny devices surgically implanted in the body, which is a complicated and risky endeavor. These implants are tested solely with disabled people who cannot move their arms and hands, and need new ways of using computers or smartphones. Neuralink, a Silicon Valley startup founded by Elon Musk, aims to implant chips under the skull, beside the brain. Synchron, run by an Australian neurologist, hopes to implant devices inside blood vessels in the neck. These efforts, like those of many other startups, aim to read brain activity directly – an enormously complex process that must be tailored to the individual. Meta is taking a simpler approach. Its technology does not require surgery. Anyone can strap on the device and start using it. Using artificial intelligence techniques, Reardon and his team have identified common electrical signals that appear when a person moves a finger, wrist or thumb. 'This idea – this kind of technology – is not new, it is decades old,' said Dario Farina, a professor of bioengineering at Imperial College, London, who has tested the technology but was not involved in the research. 'The breakthrough here is that Meta has used artificial intelligence to analyse very large amounts of data, from thousands of individuals, and make this technology robust. It now performs at a level it has never reached before.' Meta's wristband uses a technique called electromyography, or EMG, to gather electrical signals from muscles in the forearm. These signals are produced by neurons in the spinal cord – called alpha motor neurons – that connect to individual muscle fibers. Because these neurons connect directly to the muscle fibers, the electrical signals are particularly strong – so strong that they can be read from outside the skin. The signal also moves much faster than the muscles. If a device like Meta's wristband can read the signals, it can type much faster than your fingers. 'We can see the electrical signal before you finger even moves,' Reardon said. EMG has long provided a way for amputees to control prosthetic hands. But technologies that use the technique as a computer interface are only beginning to mature. In 2012, three Canadian entrepreneurs founded a company called Thalmic Labs, which built an armband called Myo that sent simple computer commands using hand gestures. With the swipe of a hand, for instance, you could switch to a new slide in a PowerPoint presentation. But the company discontinued the product several years later. Reardon started similar research after founding a company called Ctrl Labs with two other neuroscientists he had met in a Ph.D. program at Columbia University. In 2019, the startup was acquired by Meta, where it now operates within a research operation called Reality Labs. Although Reardon and his colleagues have been privately demonstrating their technology for years, they are only now beginning to publicly share their work because it is now mature enough for the marketplace. The key development is the use of AI techniques to analyse the EMG signals. After collecting these signals from 10,000 people who agreed to test the prototype, Reardon used a machine learning system called a neural network – the same breed of AI that drives ChatGPT – to identify common patterns in this data. Now, it can look for these same patterns even when a different person is using the device. 'Out of the box, it can work with a new user it has never seen data for,' said Patrick Kaifosh, director of research science at Reality Labs and one of the neuroscientists that founded Ctrl Labs. According to Reardon, who is also known as the founding father of the Internet Explorer web browser at Microsoft, Meta plans to fold the technology into products over the next few years. Last fall, the company demonstrated how its wristband could be used to control an experimental version of its smart glasses, which can take photos, record videos, play music and verbally describe the world around you. Like technologies from Neuralink and Synchron, Meta's wristband could also provide new options for disabled people. Researchers at Carnegie Mellon are testing the wristband with people who have spinal cord injuries, allowing them to use smartphones and computers even though they do not have full use of their arms or hands. Most people with these types of injuries retain the ability to activate at least some of their muscle fibers. This allows the device to read what their brain is trying to do, even though their bodies can't actually make it happen. 'We can see their intention to type,' said Douglas Weber, a professor of mechanical engineering and neuroscience at Carnegie Mellon. In a similar way, Meta's wristband lets you control a computer with the appropriate thought. Merely thinking about a movement is not enough. But if you intend to make a movement, the wristband can pick up on what you aim to do – even if you do not physically move. 'It feels like the device is reading your mind, but it is not,' Reardon said. 'It is just translating your intention. It sees what you are about to do.' When you move your arm or hand or finger, the number of muscle fibers you activate varies depending on how big or how small the movement is. If you practice using the wristband long enough, you can learn to activate a tiny number of fibers without actually moving your fingers. 'We can listen to a single neuron. We are working at the atomic level of the nervous system.' – ©2025 The New York Times Company This article originally appeared in The New York Times.
The Star
19-07-2025
- The Star
Cancer's secret weapon to evade death
Fat isn't just a guilty pleasure – it is cancer's secret weapon. New research from UT Southwestern Medical Center in the United States is shedding light on why this is the case. In a study published this month (July 2025) in the journal Nature , the researchers found that cancer cells steal fat-packed molecules from the bloodstream, allowing them to arm themselves with a potent antioxidant that shields them from death. Tumours appear to do this by reeling in lipoproteins – mole-cules that carry fats and fat-soluble nutrients like vitamin E in the bloodstream – through sugar-coated molecules on their cell surface. These sulphated glycosaminoglycans (GAGs) allow cancer cells to fortify their cell membranes with vitamin E and avoid a form of cell death called ferroptosis. Though clinical applications are still a way off, the study underscores how understanding cancer's metabolism could open new doors for treatment, said Northwestern University's Feinberg School of Medicine associate professor of urology Dr Shad Thaxton, who was not involved in the study. 'I think this paper and others in the field (emphasise) the appreciation for ferroptosis as a mechanism to kill cancer cells – that mechanism of cell death is so intimately intertwined with cell metabolism,' he said. 'I think what's interesting for people is that metabolism has a really big impact on the potential vulnerability of cancer cells to specific therapies.' Why cancer cells need fat Cancers rewire their metabolism in ways that support their growing horde of destructive cells. Some of this rewiring involves producing energy from glucose and acquiring cellular building blocks such as nucleic acids, proteins and lipids. Amassing cellular building blocks is especially crucial since a tumour's uncontrolled growth lends to it creating a hostile microenvironment where there aren't enough nutrients and other resources, said UT Southwestern Medical Center's Children's Medical Center Research Institute assistant professor Dr Javier Garcia-Bermudez, who led the study. Lipids are essential for a tumour to grow and progress. The plasma membrane of each cell is a bilayer of lipids; as cancer cells swell in number, they have to source lipids from their immediate environment or make their own to maintain their plasma membranes. Asst Prof Garcia-Bermudez said that was the prevailing theory as to why lipids are so important to cancer. Emerging research has since discovered that lipids may offer cancer cells more functional perks. For example, a September 2024 study found that cancer cells use a type of lipid called sphingolipid to go into stealth mode, thus evading detection and destruction by the immune system. Studies have also found lipids are somehow involved in ferroptosis, a type of cell death discovered in 2012. A portmanteau of 'ferrous', the Latin word for iron, and apoptosis, the scientific word for programmed cell death, ferroptosis happens when a build-up of toxic molecules called oxidants and iron overwhelms a cell, causing it to essentially rust from the inside out. 'Oxidants damage the lipids that are forming the membranes (of) a cell,' Asst Prof Garcia-Bermudez said. 'What's interesting is that cancer cells tend to produce more oxidants than normal cells,' he added, noting that there's been interest in understanding why some cancers are more susceptible to this type of damage and in using ferroptosis to kill cancer cells. GAG-ging cancer cells The crafty masters of survival that they are, cancer cells have devised ways to dodge ferroptosis. Unraveling the reason why put Asst Prof Garcia-Bermudez and his lab on a four-year journey of scientific inquiry. One of the researchers' first findings, after screening 200 metabolic genes linked to cancer, was that an enzyme called glutathione peroxidase 4 was active in tumours. This wasn't a new discovery: Studies have shown that this enzyme, which can stop lipids from degrading, plays a pivotal role in controlling ferroptosis. When glutathione peroxidase 4 was erased from a cancer cell's genome, the tumour would die, unless it was given a drug blocking ferroptosis or fed lipoproteins. 'That was a clue that lipoproteins were somehow related to ferroptosis,' said study co-author and UT Southwestern Medical Center's Eugene McDermott Center for Human Growth and Development director Prof Dr Ralph DeBerardinis. In a battery of experiments that included depriving cancer cells in petri dishes of lipoproteins and exposing them to different antioxidants, the full picture began to be unveiled. Cancer cells were intercepting lipoproteins – particularly those bearing vitamin E, a fat-soluble antioxidant – from their surrounding environment. Like a fisherman with a fishing line, cancer cells accomplished this not with the usual reels used to catch lipoproteins, but with the long, flowy sugar chains known as GAGs. These molecules are attached to a cancer cell surface through another molecule called a proteoglycan. When the scientists blocked the biochemical pathway responsible for manufacturing GAGs, this limited a lab-grown cancer cell's access to vitamin E and made it more vulnerable to ferroptosis. In mice grafted with cancer cells, cutting off the pathway slowed tumour growth. The researchers also examined 20 tumours donated by patients with clear cell renal carcinoma, the most common type of kidney cancer. These tumours had higher levels of GAGs and vitamin E – about 15 times more of the latter – compared to normal kidney tissue. Disrupting the biochemical pathway producing GAGs prevented kidney cancer cells from devouring vitamin E-laden lipoproteins, resulting in them dying by the iron hand of ferroptosis. Much more to be done Asst Prof Garcia-Bermudez and Prof DeBerardinis caution that there is much more research to be done before their study's findings have any clinical application for treating cancer. 'We know that GAGS are on the surface, they speak to the lipoproteins and they affect the uptake of lipoproteins,' Asst Prof Garcia-Bermudez said. 'But how mechanistically this happens, especially in the cancer cell, hasn't been shown before. 'If we understand how this works and we find molecular targets that maybe we can treat with drugs and block, then we have a way to specifically deplete vitamin E in the tumour.' Prof DeBerardinis said that the research does not suggest any association between dietary vitamin E and cancer risk, or how vitamin E levels correlate with cancer patient outcomes. Figuring out those possible connections would be points for future study. In the short term, he said, these findings could be used to investigate whether tumours with higher levels of GAGs or stored vitamin E are linked to patient outcomes, such as survival rates or how well they respond to treatment. Assoc Prof Thaxton said that there are currently no federally-approved cancer treatments in the US that incite ferroptosis. His lab is conducting research into synthetic lipoproteins devoid of any lipid passengers – a Trojan horse without soldiers hiding inside. The cancer cells expect to get the lipoproteins with fats like cholesterol and vitamin E, he said, but 'they end up dying of ferroptosis'. 'Our drug doesn't carry anything and it's through this mechanism by which you can kill the cell.' For Asst Prof Garcia-Bermudez and Prof DeBerardinis, their research efforts were like finding a needle in a haystack – one they hope to find more needles in. 'Our study is really exciting, but at the same time, it's a very basic discovery,' Asst Prof Garcia-Bermudez said. 'It was incredible to discover something that people have not observed in cancer before, to understand why these tumours are so resistant. I'm super excited to keep working on this.' – By Miriam Fauzia/The Dallas Morning News/tca/dpa
